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Abstract 
Objectives: Prompt antibiotic treatment of early stage Lyme borreliosis (LB) prevents progression to severe multisys-
tem disease. There is a clinical need to improve the diagnostic specificity of early stage Lyme assays in the period prior 
to the mounting of a robust serology response. Using a novel analyte harvesting nanotechnology, Nanotrap particles, 
we evaluated urinary Borrelia Outer surface protein A (OspA) C-terminus peptide in early stage LB before and after 
treatment, and in patients suspected of late stage disseminated LB.
Method: We employed Nanotrap particles to concentrate urinary OspA and used a highly specific anti-OspA mono-
clonal antibody (mAb) as a detector of the C-terminus peptides. We mapped the mAb epitope to a narrow specific 
OspA C-terminal domain OspA236-239 conserved across infectious Borrelia species but with no homology to human 
proteins and no cross-reactivity with relevant viral and non-Borrelia bacterial proteins. 268 urine samples from patients 
being evaluated for all categories of LB were collected in a LB endemic area. The urinary OspA assay, blinded to 
outcome, utilized Nanotrap particle pre-processing, western blotting to evaluate the OspA molecular size, and OspA 
peptide competition for confirmation.
Results: OspA test characteristics: sensitivity 1.7 pg/mL (lowest limit of detection), % coefficient of variation 
(CV) = 8 %, dynamic range 1.7–30 pg/mL. Pre-treatment, 24/24 newly diagnosed patients with an erythema migrans 
(EM) rash were positive for urinary OspA while false positives for asymptomatic patients were 0/117 (Chi squared 
p < 10−6). For 10 patients who exhibited persistence of the EM rash during the course of antibiotic therapy, 10/10 
were positive for urinary OspA. Urinary OspA of 8/8 patients switched from detectable to undetectable following 
symptom resolution post-treatment. Specificity of the urinary OspA test for the clinical symptoms was 40/40. Speci-
ficity of the urinary OspA antigen test for later serology outcome was 87.5 % (21 urinary OspA positive/24 serology 
positive, Chi squared p = 4.072e−15). 41 of 100 patients under surveillance for persistent LB in an endemic area were 
positive for urinary OspA protein.
Conclusions: OspA urinary shedding was strongly linked to concurrent active symptoms (e.g. EM rash and arthritis), 
while resolution of these symptoms after therapy correlated with urinary conversion to OspA negative.
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Background
Prompt antibiotic treatment of early stage Lyme borrelio-
sis (LB) can prevent progression of the disease from the 
localized stage to the early and late disseminated stages 
[1, 2]. Unfortunately, because the clinical presentation 
can be so varied, early stage disease can be misdiagnosed 
for a variety of reasons including failure to develop an 
erythema migrans (EM) rash [3–6], failure of the patient 
or clinician to recognize an EM rash, if present [4–7], 
the non-specific nature of early symptoms (fatigue, fever, 
headache, muscle and joint pains, swollen lymph nodes), 
and a negative, or ambiguous serology [8–12]. Moreo-
ver, even after a single first course of antibiotic therapy, 
a small but significant percentage of patients and experi-
mentally infected animals can continue to harbor Borre-
lia [13–15]. Thus there is a clinical need to improve the 
diagnostic specificity of early stage Lyme assays, par-
ticularly in the period prior to the mounting of a robust 
serologic response [8, 10]. In addition, it would be valu-
able to know with greater certainty whether a first round 
of therapy is successful or should be repeated because 
of Borrelia persistence [8, 10, 16, 17]. To address these 
needs we evaluated urinary Borrelia Outer surface pro-
tein A (OspA) in early stage LB using an analyte harvest-
ing nanotechnology, Nanotrap particles, to achieve high 
sensitivity [18, 19], coupled with an anti-OspA monoclo-
nal antibody (mAb) which we show herein to recognize a 
narrow specific OspA C-terminal region, OspA236-239. 
OspA26-239 sequence is conserved across infectious 
Borrelia species, but does not have sequence homology 
with human or non-Borrelia relevant pathogens.
We selected OspA for urinary monitoring of early 
stage LB for several reasons including its central role in 
the early stage of pathogenesis [20], the known shedding 
of Borrelia antigen in the urine of animals infected with 
Borrelia burgdorferi (Bb) [21], and the OspA sequence 
conservation across Borrelia species [22, 23]. OspA is a 
273 amino acid protein that folds in an elongated con-
formation spanning 80 Å from end to end. OspA binds 
to the surface of the spirochete at the N-terminus via 
a lipid anchor. The structure consists of 21 consecu-
tive antiparallel β-strands followed by a short α-helix 
in the C-terminus and can be divided into two discrete 
domains: a sandwich domain at the N-terminus and a 
barrel domain at the C-terminus [23]. The OspA barrel 
domain at the C-terminus is highly conserved across Bor-
relia pathogenic species and plays an important role in 
Bb induced immune tolerance, induction of the inflam-
matory response through TLR2 [14, 24], and host immu-
nologic recognition [20]. In this study we focused on the 
shedding of urinary OspA peptides that contain the criti-
cal C-terminus domain. Despite the strong rationale for 
evaluating Borrelia antigens in body fluids for diagnostic 
purposes in patients with LB, including cerebrospinal 
fluid and urine [25, 26], the validity of previous immuno-
assays for Borrelia proteins has remained controversial 
[27], due to questions of specificity and sensitivity. Previ-
ous immunoassays for Borrelia antigens have employed 
polyclonal antibodies raised against Borrelia culture 
lysates. These assays may have had limited sensitivity, and 
may not have been directed at a single specific conserved 
epitope of OspA lacking sequence homology with human 
proteins or non-Borrelia spirochetes. Attempts to culture 
Borrelia from infected individuals, or to measure Borrelia 
nucleic acid in blood by PCR [28] have indicated that the 
titer of Borrelia spirochetes is very low. In addition, it has 
been documented that Borrelia can be sequestered and 
persist in joint tissues [17]. Consequently the concentra-
tion of OspA antigen in urine is expected to be very low, 
well below one nanogram per mL. Thus, even though 
there has been a historical recognition of the value of 
measuring OspA antigens in body fluids, the immune-
epitope specificity and sensitivity of past methods has 
not been sufficient to address this important question.
To overcome the previous physiologic and immuno-
logic barriers to a sensitive and specific OspA immu-
noassay, we combined our novel nanotechnology to 
massively enhance the sensitivity of detection, with a 
mAb specific to a narrow C-terminal OspA domain. 
Our nanotechnology is Nanotrap particles containing 
a covalently anchored high affinity chemical bait that 
binds OspA antigen (Fig. 1a) [18, 19, 29, 30]. When the 
nanoparticles are introduced into urine, or any body 
fluid, they immediately capture and concentrate all the 
OspA in solution (Fig.  1b, c). The nanoparticle OspA 
cargo can then simply be eluted and measured by immu-
noassay (Fig.  1d). The amount of OspA captured is a 
function of the sample volume, since the Nanotrap par-
ticles bind virtually one hundred percent of the solu-
tion phase antigen in the entire volume (Fig. 1e) [18, 19, 
29, 30]. We have previously shown that the high yield, 
preservation of captured antigen, sequestration of the 
antigen into a small volume, and exclusion of unwanted 
proteins, can dramatically improve immunoassay sensi-
tivity more than one hundred fold [18, 19, 29, 30], with-
out increasing the background. In this study, we used 
anti-OspA mAb clone 0551. We verified the anti-OspA 
mAb specificity by sequencing the OspA antigen mAb-
binding epitope and verifying the epitope specificity by 
synthetic protein and peptide competition, and testing 
for cross-reactivity with non-Borrelia organisms. After 
validating the analytical sensitivity and specificity of our 
new OspA immunoassay, we then applied it to evaluate 
OspA shedding into the urine of 151 patients suspected 
of early stage, or recurrent, LB and 117 healthy controls 
(N = 268) (Table 1).
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Methods
Ethics statement
Urine samples were collected under informed consent 
from patients suspected of having Lyme disease at any 
stage from four different community physician practices 
in Northern Virginia, a high risk geographic region for 
LB. This study met the requirements for IRB approval 
(Pro00008518, Chesapeake IRB). Matched coded clinical 
records and LB serology results were also provided under 
patient consent. Immunoassay testing for urinary OspA 
utilized Nanotrap particle pre-processing and western 
blotting to evaluate the OspA analyte molecular size, and 
OspA peptide competition was applied to fully confirm a 
positive test.
Study design and human sample collection
Subjects with all stages of documented or suspected 
Lyme disease were considered eligible for the study. 
Mid-stream urine specimens were self-collected by 268 
participants. Urine samples were stored at the collec-
tion sites (Care-ID, VA, USA; Frekko Primary Care, MD, 
USA; Internal medicine of Northern Virginia, VA, USA; 
Novant Health Virginia Internal Medicine & Primary 
Care, VA, USA) at −20  °C. Samples were frozen within 
2 h of collection. Sample were then transferred to George 
Mason University and stored at −80  °C. Whole blood 
from each subject was drawn on the same day as urine 
collection. Each participant donated blood only once. 
The blood drawing procedure was performed at the phy-
sician’s office by a registered nurse. Six mL of whole blood 
was drawn into a red top tube. Blood samples were sent 
to Quest Diagnostics for Total Lyme Disease Antibody 
(EIA) and Lyme IgG and IgM Western Blot tests. Results 
of serological testing were recorded as well as treatment 
modalities and outcome, and used to correlate serology 
outcome with the presence of OspA detected in urine. 
Age matched, non-symptomatic patients with no history 
of Lyme disease as well as patients being evaluated for 
other non-Lyme infectious diseases were included in the 
Fig. 1 Nanotrap particles concentrate and preserve OspA and 
increase the effective sensitivity of the immunoassay. a Nanotrap 
particles are covalently functionalized with a high affinity bait 
that sequesters low abundance low molecular weight antigens. 
b Nanotrap particles are mixed with urine containing the Lyme 
antigen (yellow “c”) and vast excess of resident proteins (e.g. albumin). 
Nanotrap particles capture all the solution phase Lyme antigen 
(red “C”) and exclude high abundance resident proteins (gray “A”); c 
Nanotrap particles are separated from the urine. d Lyme antigens 
captured by the Nanotrap particles are eluted in a small volume 
(e.g. 0.015 mL). e Nanotrap particle pre-processing step increases 
the effective sensitivity of any analytical technology by a concentra-
tion factor e. Assuming the initial volume of urine is V = 40 mL and 
the final elution volume is v = 0.015 mL, the concentration factor 
e = V/v = 40/0.015 = 2,667
Table 1 Clinical features of patient enrolled in the diagnostic clinical trial
Patient characteristics Number
Asymptomatic non-Lyme (healthy volunteers) 117
Symptomatic non-Lyme patients (non-Lyme patients in infectious disease clinic) 3
Untreated, clinical diagnosis of LB (positive diagnosis of Lyme disease with EM rash) 24
Antibiotic treatment for a clinical diagnosis of LB, Arthritis Pos, EM Neg (positive diagnosis of Lyme disease with arthritis symptoms) 6
EM rash present at the time of urine collection during the treatment course 10
Post-treatment with alleviation of symptoms (converted to EM Neg) 8
Patients being worked up for chronic or recurrent LB with negative or inconclusive serology 100
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control group. In addition, the study set contained Lyme 
borreliosis patients before and after antibiotic treatment.
Epitope mapping of the anti‑OspA mAb
In order to identify the epitope of the anti-OspA mAb, 
partial enzymatic digestion, western blotting and mass 
spectrometry analysis were performed using Borrelia 
burgdorferi (Bb) Lyme, Grade 2 Antigen (ARP Ameri-
can Research Products) and anti-OspA mAb clone 0551 
(Santa Cruz). Bb (Lyme), Grade 2 Antigen was derived 
from Bb Strain B31 cultured in BSK II Medium. Micro-
organisms were harvested from growth medium and 
washed in PBS using low speed centrifugation. The pel-
let was resuspended in PBS and gently sonicated. The 
antigen preparation was evaluated by gel electrophore-
sis followed by silver staining and in gel trypsin diges-
tion followed by mass spectrometry. In this study, partial 
enzymatic digestion was carried out as follows: 80 μL of 
Bb Lyme antigen Grade 2 (0.2 μg/ml) was acidified with 
80 μL of 10 mM HCl (Fisher Scientific). 10 μL of 4 mg/
mL pepsin solution (Sigma) was added to the sample and 
incubated for 1 h at RT. After the incubation, the sample 
was immediately purified with ZipTip (Millipore) accord-
ing to manufacturer instructions and dried with Nitro-
gen evaporator (Microvap 118, Organomation Associate, 
Inc). The dried pepsinized sample was resuspended in 
22.5  μL of water by repeated pipetting. An aliquot of 
2.5  μL was subjected to western blot analysis with the 
anti OspA mAb described above in order to determine 
the smallest OspA pepsin fragment that retains anti-
genicity toward the antibody. The remaining amount of 
pepsinized Lyme antigen (20 μL) was subjected to SDS-
PAGE fractionation and silver staining. Bands on the 
low molecular weight region of the gel that mirrored the 
signal on the western blot were cut using a razor blade 
and subjected to in gel digestion. Samples were reduced 
with 500 μL of 10 mM dithiothreitol (DTT, Fisher Scien-
tific) in 50 mM ammonium bicarbonate (Fluka) and then 
alkylated with 500  μL of 50  mM iodoacetamide (Acros 
Organic) in 50  mM ammonium bicarbonate at room 
temperature in the dark for 20  min. Overnight enzy-
matic digestion was carried out with 0.5  µg sequencing 
grade trypsin (Promega) dissolved in 60  μL of 50  mM 
ammonium bicarbonate pH 8 at 37  °C. Solutions were 
separated from the gel pieces and saved in clean Eppen-
dorf tubes. Aliquots of 60 μL of extraction buffer (50 % 
acetonitrile, 2 % acetic acid (Acros Organic) were added 
to the gel pieces and incubated at room temperature for 
15 min. Solutions were separated from the gel pieces and 
combined with the previous ones. Samples were then 
dried using a nitrogen evaporator (Microvap 118, Orga-
nomation Associates). Samples were reconstituted in 
6  µl of 0.1  % Formic Acid and analyzed with a Thermo 
LTQ Orbitrab Mass spectrometer. After sample injection 
by autosampler, the C18 column (0.2 × 50 mm, NanoL-
CMS Solutions) was washed for 2 min with mobile phase 
A (0.1 % formic acid), and peptides were eluted using a 
linear gradient of 0 % mobile phase B (0.1 % formic acid, 
80  % acetonitrile) to 50  % mobile phase B in 90  min at 
500 nL/min, then to 100 % mobile phase B for an addi-
tional 5 min. The LTQ mass spectrometer was operated 
in a data-dependent mode in which each full MS scan 
was followed by five MS/MS scans where the five most 
abundant molecular ions were dynamically selected for 
collision induced dissociation (CID) using a normal-
ized collision energy of 35 %. Tandem mass spectra were 
searched against the NCBI Borrelia burgdorferi database 
with SEQUEST software using tryptic cleavage con-
straints. High-confidence peptide identifications were 
obtained by applying the following filter criteria to the 
search results: Xcorr versus charge 1.9, 2.2, 3.5 for 1+, 
2+, 3+ ions; ΔCn > 0.1; probability of randomized iden-
tification e0.01. Fragments identified as OspA were used 
to design 7 different 20-mer peptides. Peptides mimick-
ing the OspA fragments obtained with the procedure 
described above were synthesized by Peptide 2.0 Inc 
using standard solid phase techniques. Purity of peptides 
was assessed by chromatography and mass spectrometry 
and guaranteed to be higher than 98 %.
Synthesis of dye functionalized, Nanotrap particles
Nanotrap particles were synthesized by precipitation 
polymerization and functionalized with organic reactive 
dyes through zero-link amidation reaction as previously 
described [19]. Briefly, 4.750 g of N-isopropylacrylamide 
(NIPAm) and 0.400  g of N, N′-methylenebisacrylamide 
(BIS) were dissolved in 500 mL of MilliQ water and fil-
tered under vacuum into a three neck round bottom 
flask. 0.525  g of Acrylic Acid (AAc) were added, and 
the solution was purged with nitrogen for 30 min under 
medium stirring and then heated up to 70 °C. 0.276 g of 
Potassium Persulfate (Sigma Aldrich) was dissolved in 
5 mL of H2O and added to the reaction in order to initi-
ate the polymerization. The reaction was kept for 6 h at 
70  °C. Particles were washed 5 times by centrifugation 
(19,000 rcf, 50 min, room temperature) with MilliQ H2O 
in order to eliminate unreacted monomer. Particles were 
resuspendend in a total volume of 600 mL of water. Parti-
cles functionalization was performed by condensation of 
the primary amine contained in the dye to the carboxylic 
group of the AAc present in the nanoparticles. Briefly, 
40 mL of particles were centrifuged and the pellet was re-
suspendend in 40 mL of 0.2 M NaH2PO4 pH 5. The parti-
cles were transferred into a round bottom flask and 2 mL 
of 1  % sodium dodecyl sulfate (SDS, Sigma) 1648  mg 
of N-(3 Dimethylaminopropyl)-N′-ethylcarbodiimide 
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hydrochloride (EDC; Fluka Analytical) and 1224  mg of 
solid N-Hydroxysuccinimide (NHS; Sigma-ALBrich) 
were added. The reaction was kept for 15  min at room 
temperature under medium stirring, then the particles 
were centrifuged, and the pellet resuspended in 0.2  M 
Na2HPO4 pH 8. In parallel, 2 g of Remazol Brilliant Blue 
were dissolved in 100  mL of Na2HPO4 pH 8 and fil-
tered twice with 0.2  µm nitrocellulose membrane disk 
filter (Millipore). Particles were then transferred to the 
dye containing solution and the reaction was held over-
night at room temperature under medium stirring rate. 
The Nanotrap particles were washed by centrifugation 
(19,000 rcf, 50 min, room temperature) 6 times in order 
to eliminate the unreacted dye and then resuspended in a 
final volume of 40 mL with MilliQ H2O.
Nanotrap particle characterization
Hydrodynamic diameter and temperature dependence of 
particle size were measured via photon correlation spec-
troscopy (Submicrometer Particle Size Analyzer, Beckam 
Coulter) using water as a diluent within a temperature 
gradient from 25 to 45 °C. Dye incorporation was meas-
ured weighing lyophilized Nanotrap particles before and 
after the coupling reaction.
Urine sample handling prior to analysis
All urine used in this study was processed as follows. 
Urine samples were thawed in a water bath at room tem-
perature. Urinalysis was performed on urine samples 
using Siemens Multistix 10SG. Specific gravity was meas-
ured with digital refractometer (Atago). Urine samples 
were then centrifuged at 3,700 rcf for 10 min at 25 °C to 
remove cellular debris. Supernatant was transferred in a 
new tube. Urine pH was measured and adjusted to 5.5 
with 1 M HCl when necessary.
Nanotrap particle performance assessment with model 
solutions
Bb Lyme antigen Grade 2 (American Research Products) 
spiked in human urine was used as model solution to 
test Nanotrap particle performance. OspA Lyme antigen 
(1.2  ng) was spiked in 40  mL of human urine collected 
from healthy volunteers and processed as described 
above and incubated with 1:10 Nanotrap particle sus-
pension (5  mg/mL dry weight concentration)/urine 
solution volume. After 30 min incubation, Nanotrap par-
ticles were separated by centrifugation (16.1 rcf, 10 min, 
25  °C). Two washes were performed by re-suspending 
the Nanotrap particles in 1 mL of MilliQ H2O and cen-
trifuged at 16.1 rcf for 10 min at 25  °C. Nanotrap parti-
cles were incubated with 600 μL of elution buffer (70 % 
acetonitrile (Fisher Scientific), 10 % ammonium hydrox-
ide (Sigma)) for 30  min at 25  °C. Samples were then 
centrifuged at 16,100 rcf for 15 min at 25 °C; the eluates 
were transferred to new tubes and 50 µL of a 50 mg/mL 
D-(+)-Trehalose dihydrate (Sigma) water solution was 
added. Eluates were then dried under nitrogen flow and 
analyzed by western blot.
Patient urine processing with Nanotrap particles
In order to analyze patient urine samples, urine samples 
(40 mL) were transferred in Nalgene™ Oak Ridge High-
Speed Polycarbonate Centrifuge Tubes and incubated 
with 4 mL of Nanotrap particles (5 mg/mL) for 30 min on 
a rocker at room temperature. Samples were then centri-
fuged at 19,000 rcf for 30 min at 25 °C. Two washes were 
performed by re-suspending the nanoparticles in 2  mL 
of MilliQ H2O and centrifuging at 16,100 rcf for 15 min 
at 25  °C. Nanotrap particles were incubated with 600 
μL of elution buffer (70 % acetonitrile, 10 % ammonium 
hydroxide) for 30  min at room temperature. Samples 
were then centrifuged at 16,100 rcf for 15 min at 25  °C; 
the eluate was transferred to new tubes and 50  µL of 
D-(+)-Trehalose dihydrate solution (50 mg/mL in water) 
were added. Eluates were then dried under nitrogen flow 
and analyzed with western blot.
OspA western blot analysis
Dried Nanotrap particle eluates were resuspended in 
15 µL of MilliQ water by repeated pipetting. 5 µL of 4× 
sample buffer: 50 mM Tris HCl (Biorad) pH 6.8, 2 % SDS, 
144 mM 2-mercaptoethanol (Fisher Scientific), 10 % glyc-
erol (Sigma) and 0.01 % bromophenol blue (Fisher Scien-
tific) was added and samples were heated at 100  °C for 
10 min. Samples were loaded on 4–20 % Tris–Glycine gel 
(Invitrogen Corporation) and separated by SDS-PAGE 
gel electrophoresis. Gel was run in Tris–Glycine SDS 
running buffer using Novex X-Cell IITM Mini-Cell (Inv-
itrogen Corporation) at 120 V for 90 min. Proteins were 
transferred onto a PVDF membrane (Millipore), blocked 
with a solution of 0.2 % I-Block (Applied Biosciences) and 
0.1 % Tween 20 (Fisher) in PBS (Life Technologies). The 
membrane was incubated overnight with a mouse anti-
OspA mAb (Santa Cruz, sc-58093, Clone ID 0551). This 
mouse mAb was purified from ascites fluid by protein A 
chromatography. The final preparation was formulated 
to a protein concentration of 100 μg/ml in 0.01 M phos-
phate buffered saline, pH 7.2 and contained 0.1 % sodium 
azide. The mAb was used at a 1:100 dilution in PBS sup-
plemented with I-Block and Tween 20. After mAb incu-
bation, the membrane was washed three times for 10 min 
with 0.2  % I-Block, 0.1  % Tween 20 in PBS. The mem-
brane was incubated with a peroxidase conjugated goat 
anti-mouse IgG adsorbed against bovine, equine and 
human serum proteins (Sigma) diluted 1:5000 in 0.2  % 
I-Block, 0.1 % Tween 20 in PBS. Three washes of 10 min 
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in 0.2 % I-Block, 0.1 % Tween 20 in PBS were performed. 
Proteins were detected with an enhanced chemilumines-
cence system (Supersignal West Dura, Thermo Fischer 
Scientific, cut off for detection: mid-femtogram levels of 
target proteins) on a Kodak MM4000 Imager [31].
OspA dot blot analysis
Proteins and peptides (2 μL) were spotted with a capillary 
tube on a PVDF membrane previously wetted in methanol. 
The membrane was blocked with a solution of 0.2 % I-Block 
and 0.1 % Tween 20 in PBS. The membrane was incubated 
overnight with anti-OspA mAb clone 0551 diluted 1:100 
in 0.2  % I-Block, 0.1  % Tween 20 in PBS (4  °C) and then 
washed three times for 10  min with 0.2  % I-Block, 0.1  % 
Tween 20 in PBS. The membrane was incubated with a per-
oxidase conjugated goat anti-mouse IgG adsorbed against 
bovine, equine and human serum proteins diluted 1:5,000 
in 0.2 % I-Block, 0.1 % Tween 20 in PBS. Three washes of 
10 min in 0.2 % I-Block, 0.1 % Tween 20 in PBS were per-
formed. Proteins were detected with an enhanced chemi-
luminescence system (Supersignal West Dura, Thermo 
Fischer Scientific) on a Kodak MM4000 Imager.
In solution competition assay and solid phase 
immunodepletion
In order to verify the specificity of band reactivity of the 
anti-OspA mAb clone 0551, a competition assay was 
developed. Prior to staining, the mAb was neutralized 
by incubation with a solution containing excess OspA or 
synthetic peptides containing partial OspA sequences. 
The mAb that was bound to the neutralizing protein or 
peptide was no longer available to bind to the epitope 
transferred on the western blot membrane. The blocked 
mAb and the mAb alone were used to probe duplicate 
western blots. All other parameters of the western blot-
ting remained the same. The comparison of neutralized 
mAb to mAb alone showed which staining was specific: 
the specific staining was absent from the western blot 
membrane probed with the neutralized mAb. More in 
detail, 100  µL of anti-OspA antibody (0.1  mg/mL) was 
added to 900 µL of 0.2 % I-Block, 0.1 % Tween 20 in PBS 
and incubated overnight with 400  µL (0.1  mg/mL) of a 
custom made recombinant OspA (Genecopoeia). In par-
allel, Bb Lyme antigen Grade 2 (0.5  ng) was separated 
by 1-D gel electrophoresis and then transferred onto 
Immobilon PVDF membranes as previously described. 
OspA-saturated and un-modified antibodies were used 
to probe the PVDF membranes. Competition assays were 
also performed neutralizing the anti OspA mAb with Bb 
Lyme antigen Grade 2 (37  μg), 80  kDa OspA chimera 
recombinant protein (12 μg, Genway), and peptide frag-
ments mimicking the antibody epitope (60 μg, Additional 
file 1: Table S1, Peptide 2.0).
The peptide OspA219-235 (Peptide 2.0) was utilized for 
solid phase affinity depletion of the mAb clone 0551. The 
peptide (300 μg) was deposited on ELISA plate wells. The 
wells were washed with PBS supplemented with 0.1  % 
Tween 20 and the excess peptide removed. The wells 
were then blocked with PBS supplemented with 0.2  % 
I-Block, 0.1 % Tween 20. The mAb clone 0551 (3 μg) was 
incubated with the solid phase adsorbed peptides over-
night at 4 °C under rotation. After incubation, the super-
natant was recovered and brought to a volume of 3 mL in 
PBS supplemented with 0.2  % I-Block and 0.1  % Tween 
20. In parallel, 600 pg of Bb Lyme antigen Grade 2 were 
spiked in urine and processed through the Nanotrap par-
ticles. The immunodepleted mAb and the mAb alone 
were used side by side to stain membranes containing the 
Nanotrap particle eluates.
Reproducibility and sensitivity of the urinary OspA Lyme 
assay
In order to assess intra-assay reproducibility of the uri-
nary OspA Lyme assay, four experimental replicates were 
performed in one day as follows. Bb Lyme antigen Grade 
2 (1.2  ng) was spiked in 40  mL of urine collected from 
healthy volunteers and incubated with 4 mL of Nanotrap 
particle suspension (5 mg/mL). Samples were processed 
as described above and the Nanotrap particle eluates 
were analyzed by western blot using anti-OspA mAb 
clone 0551.
In order to determine the lower limit of detection and 
the lower limit of quantitation of the urinary OspA assay, 
different quantities of Lyme antigen (1.2, 0.6, 0.3, 0.15, 
0.075, 0.038, 0.019, and 0.009 ng) were spiked in 40 mL 
of human urine. Aliquots of 4  mL of Nanotrap particle 
suspension (5  mg/mL) were mixed with the urine sam-
ples and processed as described above. Nanotrap particle 
eluates were analyzed by Western blot. The experiment 
was repeated three times in three different days. Mul-
tiple batches of Nanotrap particles were used in this 
study. Batch validation and batch to batch reproducibility 
experiments were performed following the same protocol 
described above.
Interfering substances and cross‑reactivity with relevant 
non Bb infections
In order to exclude possible cross-reactivity of the 
mAb clone 0551 with interfering substances, a series of 
Nanotrap experiments were performed and analyzed 
using western blotting. Increasing amount of the fol-
lowing antigens were spiked in 40 mL of human urine in 
presence or absence of Bb Lyme antigen: bovine serum 
albumin, human healthy volunteer whole blood, Bar-
tonella henselae lysate (ATCC 49793), Babesia microti 
(ATCC PRA-399), Epstein-Barr virus (EBV) Inactivated 
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P3HR1 Cell Extract (Advanced Biotechnologies Inc.; 
10-501-001), Herpes Simplex virus-1 (HSV-1) Inacti-
vated Vero Cell Extract (Advanced Biotechnologies Inc; 
10-515-001), Cytomegalovirus (CMV) HEK293 Cell 
Lysate (Sino Biological Inc.; 10202-VCCH1L), Hepa-
titis C Virus HEK293 Cell Lysate (Sino Biological Inc.; 
10202-VCCH1L). These samples were processed follow-
ing the protocol described above.
Data analysis
Statistical Chi squared test for equality of proportions 
was applied in order to correlate urinary OspA outcome 
(detectable or non-detectable) to clinical LB diagno-
sis and serology. Power calculations were performed in 
order to estimate the power of the test, given the num-
ber of samples in each group, the proportions of urinary 
OspA outcome, and a significance level of 0.05. Calcula-
tions were performed using R software (http://www.r-
project.com).
Western blotting band intensity was quantified with 
ImageJ software (http://imagej.nih.gov/ij/index.html) by 
selecting the area of interest and calculating area, mean 
and standard deviation of selection per software instruc-
tions. Blast analysis and protein alignment was performed 
using pBLAST [32]. Search parameters were as fol-
lows: query sequence: KTSTLTISVNSKKTTQLVFTKQ 
DTITVQKYDSAGT, Database Name: non redundant, 
Program: BLASTP 2.2.31+.
Results
Mass spectrometry sequencing and peptide competition 
reveals the OspA C‑terminal epitope recognized by the 
anti‑OspA mAb
The epitope of OspA recognized by the mAb clone 
0551 was sequenced and verified by peptide dot blot 
and peptide competition. First, the Bb Lyme antigen 
Grade 2 (81  % OspA content, Additional file  1: Fig-
ure  S1) was partially digested with pepsin and the pro-
tease derived fragments were split into two aliquots. 
One aliquot was analyzed by western blotting with the 
anti-OspA mAb clone 0551. In parallel, the second ali-
quot of pepsin fragments was analyzed by SDS-PAGE 
and silver stained. The band in the SDS-PAGE mirror-
ing the smallest peptide fragment recognized by the 
mAb was cut out and processed for mass spectrom-
etry analysis (Fig.  2). The fragment KTSTLTISVNSKKT 
TQLVFTKQDTITVQKYDSAGT (OspA219-253, Fig.  2, 
Additional file  1: Table  S1) was the smallest sequence 
that reacted with the mAb clone 0551. This sequence is 
located on the C-terminal region of the protein (Fig. 3a, 
b). Two overlapping peptides, Peptide 5 (OspA219-239)   
=  KTSTLTISVNSKKTTQLVFTK and peptide 6 (OspA 
234-253)  =  QLVFTKQDTITVQKYDSAGT (Additional 
file 1: Table S1), were synthesized and evaluated against 
control peptides from other regions of the molecule for 
their reactivity with the mAb (Fig.  3c, Additional file  1: 
Figure  S2). The overlapping region of these peptides 
(OspA236-239 = VFTK) was found to be necessary and 
sufficient for antibody recognition via dot blot (Addi-
tional file  1: Table  S1, Fig.  3c), solution phase competi-
tion and immunoaffinity solid phase competition (Fig. 4). 
The flanking regions, highly variable in the Borrelia burg-
dorferi sensu strictu and across different Borrelia species 
were devoid of immunoreactivity with the mAb clone 
0551 (Figs. 3, 4, Additional file 1: Table S1).
The anti‑OspA mAb epitope is conserved in common 
pathogenic species of Borrelia
The antigenic epitope OspA236-239 is highly con-
served among major pathogenic Borrelia strains, which 
include: Borrelia burgdorferi sensu stricto, several Borre-
lia burgdorferi sensu lato (Borrelia garinii, Borrelia val-
aisiana, Borrelia bissettii, Borrelia afzelii, and Borrelia 
spielmanii) and additional more recently characterized 
pathogenic species (Additional file  1: Table  S2). BLAST 
analysis [32] performed on the sequence of the fragment 
OspA219-253 KTSTLTISVNSKKTTQLVFTKQDTITVQ 
KYDSAGT identified by mass spectrometry showed 
that it was not homologous to any human protein and 
not homologous to any other non-Borrelia spirochetes 
(Additional file 1: Table S2).
Nanotrap particles functionalized with a high affinity 
chemical bait capture urine OspA with high efficiency 
and yield
Nanotrap particles were functionalized with a series of 
chemical baits [18, 19] that bind solution phase analytes 
with high affinity (Fig. 5, Additional file 1: Table S3 and 
S4, Figure  S3). The reactive dye Remazol Brilliant Blue 
[19] had the highest affinity for OspA in urine (Fig. 5a, b). 
In addition, we document the relationship between the 
amount of dye bait in the particles and the depletion of 
antigen from the supernatant, providing clear evidence 
of 100 % antigen depletion from the solution phase and 
saturation of binding (Fig. 5c, d). The Nanotrap particles 
with no dye bait can volume sequester some antigen [18, 
19], but not concentrate the analyte from the surround-
ing solvent volume, because there is no affinity capture 
without the dye bait [19] (Fig.  5b). Multiple Nanotrap 
particle batches were used throughout the study. Under 
CAP laboratory certification, we conducted routine 
batch to batch verification, and batch validation, with 
specific release criteria (%CV  <  10  %) (Fig.  6). A series 
of v/v ratios (nanoparticle volume/sample volume) were 
tested in order to optimize OspA capture (achieving 
greater than 95 % capture and elution yield of all solution 
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phase OspA (Additional file  1: Fig.  S4). Nanotrap par-
ticle pre-processing will increase the effective analyte 
concentration more than 2000 fold, as a function of the 
volumetric ratio (Fig. 1e) (The initial volume of urine is 
V = 40 mL and the final elution volume is v = 0.015 mL, 
V/v = 40/0.015 = 2667).
Quantitative OspA C‑terminal peptide western blotting 
following Nanotrap particle processing of urine yields high 
precision and high sensitivity
Spiked-in samples were pre-processed with Nanotrap 
particles and western blot immunoassay followed by 
densitometric scanning. Densitometric analysis of the 
OspA specific band indicated a high level of intra-
assay precision (n =  4, %CV =  7  %) for the nanopar-
ticle concentration/immunoblotting method achieving 
a lowest limit of detection (LLD) of 1.7  pg/mL start-
ing from 40 mL of urine (Fig. 7). The dynamic range is 
1.7–30 pg/mL.
Lack of cross‑reactivity with relevant non Borrelia 
infections
OspA antigen, at the expected full length size of the mol-
ecule, was the single band detected by Western blotting 
after Nanotrap processing of OspA containing human 
urine spiked with viral lysates (Herpes Simplex Virus-
1, Epstein-Barr virus, Cytomegalovirus, and Hepatitis 
C Virus), and bacterial lysates (Lyme disease co-infec-
tion microorganisms Bartonella henselae and Babesia 
microti) (Fig.  8). Thus viral and non Borrelia bacterial 
lysates do not interfere with the Nanotrap particle cap-
ture of the antigen and with the mAb recognition and 
are devoid of immunoreactivity with the mAb. Similarly, 
increasing concentrations of interfering Bovine Serum 
Albumin and blood (hemoglobin) showed no cross-reac-
tivity with the mAb (Additional file 1: Figure S5). West-
ern blotting of urine samples from a positive control LB 
urine verified that Nanotrap particle pre-processing step 
is necessary to detect the expected low concentration 
Fig. 2 Mapping the OspA antigen epitope. Bb Lyme antigen was partially digested with pepsin and the protease derived fragments were split into 
two aliquots. One aliquot was analyzed by western blotting with the anti-OspA mAb clone 0551. In parallel, the second aliquot of pepsin fragments 
was analyzed by SDS PAGE and silver stained. The band in the SDS PAGE mirroring the smallest peptide fragment recognized by the mAb was cut 
out and processed for mass spectrometry analysis. MS/MS spectra of the smallest peptides that reacted with the mAb are shown
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of OspA in urine of patients with LB (Additional file  1: 
Figure S6).
Positive cases were confirmed by competition with OspA 
protein
Protein competition using a recombinant protein con-
taining the OspA C-terminal mAb binding domain 
OspA236-239 was employed for the evaluation of patient 
urine specimens to ensure complete immunoassay speci-
ficity and to evaluate the presence of C-terminal frag-
ments of OspA (Fig. 9a). A direct Western immunoblot 
(Fig. 9b) and a competition assay were performed on the 
patient’s urine sample (Fig.  9b). An individual patient’s 
urinary OspA was scored as positive only if both assay 
methods were judged positive. Positive OspA bands are 
normally visible in the 28–30 kDa range although lower 
Fig. 3 Narrow OspA236-239 region is conserved across different Borrelia species and binds to mAb clone 0551. a Crystallography structure of OspA 
(Protein Data Bank PDB ID# 1FJ1): the epitope of the mAb is highlighted in red. b BLAST search against different Borrelia strains and species shows 
that the mAb clone 0551 epitope is highly conserved whereas the flanking regions are variable. c Synthetic peptides mimicking the OspA236-239 
region interact with the mAb in a dose dependent manner (dot blot analysis, 1, 2, 3 = Bb Lyme antigen 0.5, 5, and 10 ng, respectively; 4, 5, and 
6 = OspA219-253 0.5, 1, and 2 μg, respectively; 7, 8, and 9 = OspA219-235 0.5, 1, and 2 μg, respectively; 10, 11, and 12 = OspA240-253 0.5, 1, and 
2 μg, respectively). Negative control peptides (OspA219-235 and OspA240-253) containing flanking regions but lacking the OspA236-239 sequence 
were devoid of immunoreactivity with the mAb clone 0551
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molecular bands can be detected and successfully com-
peted suggesting the presence of smaller OspA C-termi-
nal domain protein fragments in urine. In some patients 
a high molecular weight band at ~60  kDa was detected 
and this was determined to be a dimer of OspA by mass 
spectrometry sequencing (Additional file  1: Figure  S1). 
The higher molecular weight band was fully competable 
by the recombinant OspA (Fig. 9b).
Borrelia OspA is shed in the urine of early stage Lyme 
patients
Untreated patients with a clinical diagnosis of acute LB
Urinary Borrelia OspA protein was present in untreated 
patients who were suspected of having early stage cuta-
neous LB, objectively classified under CDC guidelines 
by the presence of a characteristic erythema migrans 
(EM) rash, with or without concurrent symptoms such as 
fever, malaise, or neurologic symptoms (e.g. Bell’s Palsy) 
and positive serology (Table  1). Serology was assessed 
with the two tier testing algorithm and considered posi-
tive if (a) the first tier enzyme immunoassay was positive 
or equivocal and (b) the second tier IgG or IgM western 
blot was positive (5/10 bands and 2/3 bands for IgG and 
IgM, respectively). According to CDC recommendation, 
a positive IgM western blot is valid only for early disease, 
that is, in the first month of illness [33]. 24/24 patients 
exhibiting a characteristic cutaneous infection (EM rash) 
at the time of urine collection, were positive for urinary 
OspA peptides containing the C-terminal domain rec-
ognized by the anti-OspA mAb (Figs.  3b, 9c). Most of 
the positive OspA peptide bands were in the range of 
28–32  kDA, but in some cases smaller fragments and a 
higher molecular weight band (that could be competed) 
in the range of 20–28 and ~60 kDa were noted (Fig. 9b). 
Thus the urinary shedding of OspA is likely to include 
OspA antigen modified by proteases. In contrast, none of 
117 untreated, control patients shed urinary OspA C-ter-
minal antigen who were non symptomatic (Chi squared 
p value <2.2e−16; significance = 5 %, power 100 %). Sam-
ples classified negative for OspA did not have detect-
able bands in the 20–32 kDa range (Fig. 9d). For the 24 
patients that were EM positive and also urinary OspA 
positive at the time of urine collection, 12 became LB 
serology positive by CDC criteria for early diagnosis [33], 
5 were serology negative [33], 3 were serology equivocal 
and 4 were not done (ND, Table 2). 3 untreated patients 
who were LB serology negative, and EM negative, but 
positive for joint symptoms and fatigue, were negative 
(0/3) for urinary OspA (Table  2). Specificity of the uri-
nary OspA antigen test for later serology outcome was 
87.5  % (21 urinary OspA positive/24 serology positive, 
Chi squared p = 4.072e−15, Table 3).
The Nanotrap system used in this study has been suc-
cessfully applied in the past to verify the presence of 
OspA and OspB in tick vectors [30]. Fourteen ticks 
(females and males collected in Pennsylvania and Vir-
ginia) were analyzed. Four out of 14 ticks gave a strong 
positive signal in the Nanotrap particle system. The exact 
same band pattern of OspA identified in the extracted 
tick was also seen in patient’s urine in this study (Fig. 9).
Treated patients with a clinical diagnosis of acute LB
We evaluated the urinary OspA shedding of patients 
who presented to a community infectious disease clinic 
with onset of cutaneous or systemic symptoms and 
were immediately treated with antibiotics based on a 
clinical diagnosis of LB (Tables  1, 2, Additional file  1: 
Table S5). Urinary OspA was scored positive or negative 
as described above without knowing the clinical out-
come, and then compared to the clinical diagnosis based 
on anonymous coded patient records. Urinary OspA was 
Fig. 4 Peptides containing the narrow OspA236-239 region were 
successfully utilized for antibody competition and immunodeple-
tion. a 600 pg of Bb Lyme antigen Grade 2 were spiked in human 
urine. Samples were processed through the Nanotrap particles and 
analyzed by western blot. Lane 2, 4 and 6 were obtained staining the 
western blot membranes with the mAb clone 0551 alone, the mAb 
neutralized with OspA219-253 peptide, and the mAb neutralized with 
a combination of OspA219-235 and OspA240-253, respectively. The 
peptide containing the OspA236-239 region successfully competed 
the mAb, whereas peptide missing the OspA236-239 region failed 
to compete the mAb clone ID 0551. b Peptide OspA219-235 was 
utilized for solid phase affinity depletion of the mAb clone 0551. The 
peptide (30 μg) was deposited on ELISA plate wells. The wells were 
washed and the excess peptide removed. The wells were blocked 
with PBS supplemented with 0.2 % I-Block, 0.1 % Tween 20. The mAb 
clone 0551 (3 μg) was incubated with the solid phase adsorbed 
peptides overnight. After incubation, the supernatant was recovered 
and brought to a volume of 3 mL in PBS supplemented with 0.2 % 
I-Block and 0.1 % Tween 20. In parallel, 600 pg of Bb Lyme antigen 
Grade 2 were spiked in urine and processed through the Nanotrap 
particles (lane 2 and 4). Lane 2 and 4 were obtained staining the 
western blot membranes with the mAb alone (3 μg) and the mAb 
after immunodepletion, respectively. There is no immunoreactivity in 
the mAb preparation after immunodepletion (lane 4). This is a further 
confirmation of the absence of non-specific signal in the mAb clone 
0551 preparation
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compared to LB western blot serology for each patient. 
A subset of the treated patients donated a urine speci-
men at a time in the course of antibiotic therapy when the 
EM rash was still present. 10/10 treated patients with a 
concurrent EM rash at the time of urine collection were 
positive for urinary OspA antigen C-terminal containing 
peptides. Of these 10, four (4/10) post treatment were 
LB serology positive. Six of six (6/6) patients undergoing 
antibiotic therapy for a clinical diagnosis of LB who had 
systemic symptoms such as joint pain or neurologic symp-
toms, but were EM negative, were also positive for urinary 
OspA. All of these patients became serology positive by 
CDC criteria [33]. 8 patients who were initially positive 
for urinary OspA antigen were clinically diagnosed as 
symptom free (resolution of EM rash) after a successful 
course of antibiotic therapy for a clinical diagnosis of LB. 
None (0/8) asymptomatic post treated patients were posi-
tive for urinary OspA (Fig. 9e) and four (4/8) were subse-
quently LB serology positive. Thus urinary OspA antigen 
shedding appears, in this study group, to closely parallel 
the concurrent presence of symptoms.
Treated patients under clinical evaluation for persistent or 
recurrent LB
Urinary OspA shedding was further evaluated in a cohort 
of 100 patients in a Lyme endemic geographic region who 
were under clinical surveillance for persistent or recurrent 
LB. All of these patients had been previously treated with 
antibiotics, and all patients had been followed because of 
prolonged chronic functional symptoms such as arthral-
gias, neurocognitive symptoms, and fatigue. All of these 
patients lacked a CDC criteria defined LB serology posi-
tive IgG western blot serum test at the time of urine col-
lection [34]. According to the IDSA (Infectious Diseases 
Society of America) 2006 and 2010 guidelines [35, 36], 
“To date, there is no convincing biologic evidence for the 
existence of symptomatic chronic B. burgdorferi infection 
among patients after receipt of recommended treatment 
Fig. 5 Remazol Brilliant Blue Nanotrap particles show the highest affinity for OspA among the tested dyes. a Nanotrap particles Lyme antigen 
(1 ng) was spiked in 500 µL of human urine from healthy volunteers and incubated with Nanotrap particles functionalized with different dyes. 
After Nanotrap particles processing, Lyme antigen is successfully depleted from supernatants (S) and easily detectable in the eluate (E). Lanes 1 
ladder; 2 Lyme antigen 0.1 ng; 3 Supernatant Remazol Brilliant Blue Nanotrap 1; 4 Eluate Remazol Brilliant Blue Nanotrap 1; 5 Supernatant Remazol 
Brilliant Blue Nanotrap 2; 6 Eluate Remazol Brilliant Blue Nanotrap 2; 7 Supernatant Reactive Blue 4 Nanotrap; 8 Eluate Reactive Blue 4 Nanotrap; 
9 Supernatant Diamine Green Nanotrap; 10 Eluate Diamine Green Nanotrap. b Nanotrap particles without dye bait can volume sequester some 
antigen but not concentrate the analyte from the surrounding solvent volume, in absence of affinity capture. The amount of OspA in the dye free 
particles is approximately 10 % of the control solution reflecting the urine solution/Nanotrap particle volumetric ratio (10:1). Lanes 1 ladder; 2 Lyme 
antigen 1 ng; 3 Negative control = urine without Bb antigen, 4 Supernatant vinyl phenyl boronic acid Nanotrap 1; 5 Eluate vinyl phenyl boronic acid 
Nanotrap 2; 6 Supernatant acrylic acid Nanotrap; 7 Eluate acrylic acid Nanotrap; 8 Supernatant allylamine Nanotrap; 9 Eluate allylamine Nanotrap; 10 
Supernatant Remazol Brilliant Blue Nanotrap; and 11 Eluate Remazol Brilliant Blue Nanotrap. c Relationship between the Remazol Brilliant Blue in the 
particles and depletion of the antigen in the supernatant: 100 % antigen depletion from the solution phase and saturation of binding. Lane 1 ladder, 
lane 2 initial solution, lanes 3–7 supernatants after incubation of a urine solution containing 0.6 ng of Bb antigen with Nanotrap particles functional-
ized with increasing concentration of Remazol Briliant blue: 34, 68, 171, 343, 686 n moles, respectively. d ImageJ quantification of the optical density 
in (c). Y axis: Antigen sequestered in the Nanotrap particles obtained as difference between the initial solution (lane 2) and the supernatants (lanes 
3–7) in (c). X axis: μ moles of Remazol Brilliant blue in the Nanotrap particles
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regimens for Lyme disease.” In contrast, according to 
ILADS (The International Lyme and Associated Diseases 
Society), the diagnosis of persistent Lyme disease is a real 
phenomenon and often requires clinical judgment to be 
characterized [34]. Due to the frequent nonspecific nature 
of complaints and insensitivities of diagnostic studies, the 
clinician is forced to weigh the risk profile of any individ-
ual presenting with what may be considered Lyme disease. 
This includes the risk of tick exposure and the presenting 
symptom complex [8, 34, 37–42]. In this study, urinary 
OspA scoring was performed blinded to the patient diag-
nosis or clinical findings. After the urine OspA scoring 
was completed, the clinical data was unblinded. For this 
special group of previously treated patients under surveil-
lance for persistent or recurrent LB, 41/100 were positive 
for urinary OspA C-terminal peptides (Additional file  1: 
Table  S6). This percentage of patients with positive uri-
nary OspA is in keeping with the range of seven previous 
Fig. 6 Nanotrap particle batch validation and batch to batch reproducibility. a Nanotrap particles are incubated with increasing amount of Bb 
Lysate spiked in 40 mL of urine; Lane 1: Ladder; Lane 2: Positive control Bb Lyme antigen Grade 2 1 ng; Lane 3: Positive control Bb Lyme antigen 
Grade 2 0.28 ng; Lanes 4–9: eluate of Nanotrap particles incubated with increasing concentrations of Bb antigen in 40 mL of urine: 0; 1.7; 3.5; 7; 15; 
30 pg/mL, respectively b Performance comparison of two batches of Nanotrap particles, NT294 and NT306. Lane 1: Ladder; Lane 2: Positive control 
Bb Lyme antigen Grade 2 60 pg; Lane 3: eluate of Nanotrap particles batch NT296 incubated with 1 pg/mL Bb antigen urine solution (40 mL); Lane 
4: eluate of Nanotrap particles batch NT296 incubated with 16 pg/mL Bb antigen urine solution (40 mL); Lane 5–10: eluate of Nanotrap particles 
batch NT306 incubated with increasing concentrations of Bb antigen urine solution (40 mL) 0; 2; 4; 8; 16; 32, respectively. c Performance comparison 
of multiple batches of Nanotrap particles (%CV = 9 % and 5 % at 2 pg/mL and 16 pg/mL Bb antigen in 40 mL of urine, respectively). Lane 1: ladder; 
lane 2: Positive control Bb Lyme antigen Grade 2 16 pg; lane 3: eluate of Nanotrap particles batch NT283 incubated with 40 mL of urine without Bb 
Lyme antigen Grade 2; lanes 4–5: eluates of Nanotrap particles batch NT283 incubated with 2 and 16 pg/mL Bb Lyme antigen Grade 2 urine solu-
tion (40 mL); lanes 6–7: eluates of Nanotrap particles batch NT294 incubated with 2 and 16 pg/mL Bb Lyme antigen Grade 2 urine solution (40 mL); 
lanes 8–9: eluates of Nanotrap particles batch NT306 incubated with 2 and 16 pg/mL Bb Lyme antigen Grade 2 urine solution (40 mL). d Yield of 
Nanotrap particle pre-processing is 93 %. Lane 1: ladder; lane 2: Bb antigen 320 pg, lane 3: eluate of Nanotrap particles batch NT283 incubated with 
40 mL of urine without Bb Lyme antigen; lane 4: supernatant; lane 5: eluate of Nanotrap particles batch NT283 incubated with 8 pg/mL Bb Lyme 
antigen Grade 2 urine solution (40 mL)
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studies conducted in endemic areas where patients were 
being evaluated for suspected Lyme disease: 7–31 % active 
disease and 5–20  % previous Lyme disease in endemic 
areas [43–49].
Discussion
Value of a specific and sensitive urine test for Bb OspA
The goals of the study were to answer the following ques-
tions: Is Bb OspA antigen shed in the urine of patients 
with LB at early stage disease prior to the development 
of a positive serology? What is the urinary OspA concen-
tration range? Is the OspA antigen containing the C-ter-
minus epitope shed into urine as a full length protein or 
as fragments? Does the presence of OspA in the urine of 
a patient with an EM rash suspected of having LB cor-
relate with the concurrent or later development of posi-
tive serology (western blot or ELISA)? If urinary OspA is 
present prior to antibiotic therapy, is it reduced or absent 
after successful therapy (resolution of symptoms)? What 
percentage of patients suspected of having persistent or 
recurrent LB contain urinary OspA C terminal domain 
antigen?
OspA mAb specificity
In this study, the specificity of the mAb clone 0551 used in 
the Nanotrap test was verified in three ways: (1) peptide 
competition and immune affinity depletion, which revealed 
absolute specificity for a narrow C-terminus sequence of 
OspA that was conserved in all the Borrelia burgdorferi 
sensu latu species. (2) Viral and bacterial lysates of HSV, 
EBV, HCV, CMV, Babesia, and Bartonella tested at the 
same antigen concentration as the OspA Borrelia anti-
gen were devoid of immunoreactivity with the mAb clone 
0551and did not interfere with the recognition of OspA. 
This was done using the entire Nanotrap concentration sys-
tem with test antigens spiked in human urine. (3) BLAST 
sequence analysis of HSV, EBV, HCV, CMV, Babesia, Bar-
tonella, human genome database and non Borrelia spiro-
chetes showed no significant similarity with the defined 
and verified C-terminus OspA epitope domain. It’s impor-
tant to note that the specific domain recognized by the 
mAb clone 0551 is OspA236-239. This region is quite dis-
tant on the OspA molecule from the region that was shown 
in the past to have sequence similarity with human proteins 
(OspA154-173 = GSGKAKEVLKGYVLEGTLTA [50]).
Fig. 7 Lower limit of detection/quantitation and reproducibility (%CV = 7 %) of the urinary OspA Lyme test. a Sensitivity studies on three inde-
pendent replicates: lower limit of detection (LLD) is 1.7 pg/mL. The lower limit of quantitation (LLQ) is 4.2 pg/mL for a 40 mL urine sample input vol-
ume. (Background estimate = 1071 AU, standard deviation (SD) = 323 AU. LLD = background + 2*SD, LLQ = background + 10× SD; polynomial 
equation y = −19.026x2 + 1160x − 248.76, R2 = 0.9971, was used to estimate the corresponding x value (1.7 pg/mL and 4.2 pg/mL, respectively)). 
Insert: 1 ladder; 2 Bb Lyme antigen control 1000 pg; 3 Eluate from Nanotrap particles incubated with 40 mL of volunteer urine containing no Bb 
Lyme antigen, negative control; 4–10 Eluate from Nanotrap particles incubated with 40 mL of volunteer urine containing decreasing concentrations 
of OspA, 30, 15, 7.5, 3.75, 1.9, 0.9, and 0.47 pg/mL, respectively. b Within run assay %CV is 7 %. Lyme antigen (1200 pg) was spiked in 4 urine aliquots 
(40 mL) and incubated with 4 mL of Nanotrap particles. Band intensity was measured with Image J. Within run %CV = 7 %. 1 Ladder; 2 OspA Lyme 
antigen control 200 pg, 3–6 Replicates of Nanotrap particle processed spike-in samples
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Based on the conservation of the epitope OspA236-
239, the specificity of our test should extend to all the 
pathogenic Borrelia species in the US and Europe (Fig. 3). 
In the future, it will be important to verify the sensitiv-
ity and specificity obtained in this study to geographically 
diverse populations.
Shedding of OspA protein in the urine of patients with a 
diagnosis of early stage Lyme borreliosis
In order to achieve a test that can detect LB at the earliest 
stage, even before an immune response is mounted, we 
chose the well studied molecule OspA, but we focused 
on a novel epitope. Borrelia OspA plays a central role in 
the survival of the spirochete in the tick vector [51–53]. 
During the initial phases of a cutaneous infection fol-
lowing a tick bite, OspA is recognized by innate immune 
cell Toll-like receptor TLR2, and together with TLR8, 
initiates a cascade of proinflammatory cytokines, such 
as interleukin 1 and T-helper derived cytokines that are 
thought to mediate the initial inflammatory reaction [54]. 
OspA is upregulated in response to inflammatory cues by 
host-adapted Bb later in the course of disease [55–57]. In 
previous studies, specific complexed antibody to whole 
Bb and recombinant OspA were detected in 10 of 11 of 
the EM positive patients compared to 0 of 20 endemic 
area controls [20]. IgM was the predominant isotype rec-
ognizing OspA in these EM patients. Free IgM to OspA 
was found in half the EM cases. IgM to OspA was also 
detected in 10 of 10 European patients with EM who also 
had reactive T cells to recombinant OspA [20]. In longi-
tudinal studies of serial serum samples from untreated 
patients (collected prior to the use of antibiotic therapy 
for Lyme disease treatment), elevation of IgG reactivity to 
OspA parallels the rising of the antibody response to Bb 
proteins [58, 59]. Animal models have shown that Bor-
relia antigens are shed into the urine following infection 
[21]. For example in early studies of Borrelia infection 
of mice in the wild, 76 % of 50 mice (white-footed mice 
Peromyscus leucopus) shed Borrelia antigens, including 
OspA, into the urine [21]. In keeping with animal model 
studies, OspA antigen shedding prior to antibiotic treat-
ment occurred in the urine of 24/24 patients with a posi-
tive EM rash and clinical symptoms of LB (Table  2). In 
contrast, none of 117 untreated patients shed urinary 
OspA C-terminal antigen who were non symptomatic, or 
were non symptomatic and concurrently serology nega-
tive for LB.
OspA antigen is shed into urine either as a full length 
protein, or as a fragment containing the C‑Terminus 
domain
Pepsin fragmentation, followed by mass spectrometry 
sequencing and synthetic peptide competition, identi-
fied the anti-OspA mAb binding domain to reside in 
the C-terminus region of OspA (Fig. 2, Additional file 1: 
Table S1). In previous studies, IgG titers to OspA (and to 
a lesser extent, OspB) in untreated patients [20] correlate 
directly with severity of chronic Lyme arthritis, while IgG 
titers to the C-terminal third of OspA (OspA168–273) 
correlate with both severity and duration, suggesting the 
Fig. 8 Viral and Lyme disease co-infection pathogens were devoid 
of immunoreactivity with the mAb clone 0551. Infection with these 
common non-Lyme pathogens do not generate a false positive for 
Borrelia in the present Nanotrap test. a Herpes simplex 1 and Epstein 
Barr viral lysates were mixed with urine in presence and absence of 
Bb antigen. Samples were processed with Nanotrap particles and 
analyzed with western blot. Lane 1 ladder, lane 2 Bb antigen 1 ng; 
lanes 3–7 eluates of Nanotrap particles incubated with urine without 
Bb antigens (lane 3), 25 pg/mL Bb antigen in urine 40 mL (lane 4), 
HSV-1 lysate (1 μg in 40 mL of urine) (lane 5), EBV lysate (1 μg in 40 mL 
of urine) (lane 6), HSV-1 lysate (1 μg in 40 mL of urine) plus EBV lysate 
(1 μg in 40 mL of urine) plus Bb antigen (1 ng in 40 mL of urine) (lane 
7). (B) Hepatitis C and Cytomegalovirus viral lysates were mixed with 
human urine in presence and absence of Bb antigen. Lane 1: ladder, 
lane 2 Bb antigen 1 ng; lanes 3–7: eluates of Nanotrap particles incu-
bated with urine without Bb antigen (lane 3), 25 pg/mL Bb antigen in 
urine 40 mL (lane 4), HCV lysate (1 μg in 40 mL of urine) (lane 5), CMV 
lysate (1 μg in 40 mL of urine) (lane 6), HCV lysate (1 μg in 40 mL of 
urine) plus CMV lysate (1 μg in 40 mL of urine) plus Bb antigen (1 ng 
in 40 mL of urine) (lane 7). c Bartonella henselae and Babesia microti 
lysates were spiked in human urine in presence and absence of Bb 
antigen. Lane 1: ladder, lane 2: Bb antigen 1 ng; lanes 3–9: eluates of 
Nanotrap particles incubated with urine without Bb antigen (lane 3), 
25 pg/mL Bb antigen in urine 40 mL (lane 4), Bartonella lysate (1 ng in 
40 mL of urine) (lane 5), Babesia lysate (10 ng in 40 mL of urine) (lane 
6), red blood cells (10 ng in 40 mL of urine) (lane 7), Bartonella lysate 
(10 ng in 40 mL of urine) plus Babesia lysate (10 ng in 40 mL of urine) 
plus Bb antigen (1 ng in 40 mL of urine) (lane 8), 40 mL of urine of a 
patients with Bartonella positive and Borrelia negative serology at the 
time of urine collection (lane 9)
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strongest causal link with epitopes contained within this 
fragment [59]. The C-terminal quarter of OspA (218-273) 
is also highly conserved among a large number of patho-
genic species of Borrelia sequenced to date [22, 23]. The 
specific C-terminus peptide sequence (Additional file  1: 
Table  S1) of the antigenic epitope showed no sequence 
homology with any human protein and did not have any 
sequence homology with non-Borrelia spirochetes. The 
size of the OspA antigen shed into the urine in the pre-
sent study (Fig.  9) was close to the expected size of the 
full length OspA protein (approximately 31 kDa) which is 
small enough to be filtered through the kidney glomeruli. 
In some cases fragments of OspA containing the C-ter-
minus fragment epitope were detected below the size of 
Fig. 9 Nanotrap particles are necessary to detect urinary OspA in the urine of acute Lyme patients. Urinary OspA bands reverts to undetectable 
after successful treatment. Band specificity is assessed through competition assay. a Conditions for an optimal competition assay were established. 
1 ng (lanes 2, 5, and 8) and 0.05 ng (lane 3, 6, and 9) of Bb Lyme antigen Grade 2 were spiked in urine. Lanes 2 and 3 were obtained with mAb clone 
0551 alone. Lanes 5 and 6 were obtained with mAb neutralized with recombinant OspA. Reduced signal demonstrates high specificity. Lanes 8 and 
9 were obtained with the mAb neutralized with Bb Lyme antigen Grade 2. Absence of signal with the neutralized antibody demonstrates specificity 
to OspA. b Competition assay was performed on all patient samples. Positive test outcomes show minimal or no binding of neutralized mAb to 
specific bands. Example competition assay for a Lyme disease patient is shown. 1 ladder; 2 Bb Lyme antigen Grade 2 OspA 1 ng; 3 initial Solu-
tion positive control (0.5 ng in 40 mL of urine processed through the Nanotrap particles); 4 supernatant positive control (0.5 ng in 40 mL of urine 
processed through the Nanotrap particles); 5 eluate positive control (0.5 ng in 40 mL of urine processed through the Nanotrap particles); 6 initial 
solution negative control (40 mL of urine processed through the Nanotrap particles); 7 supernatant negative control (40 mL of urine processed 
through the Nanotrap particles); 8 eluate negative control (40 mL of urine processed through the Nanotrap particles); 9 initial solution patient 180; 
10 supernatant patient 180; 11 Eluate patient 180; 12 initial solution patient 180; 13 supernatant patient 180; 14 eluate patient 180. Membrane con-
taining Lanes 1–11 was probed with the mAb alone, whereas membrane containing lanes 12–14 was probed with the mAb clone 0551 neutralized 
with recombinant OspA. c Lane 1 ladder, lane 2 Bb antigen 1 ng; Lanes 3–12: example of patient urine samples demonstrating presence of OspA. 
Positive OspA bands are normally visible in the 28–30 kDa range although lower molecular bands can be detected and successfully competed 
suggesting the presence of smaller-than-full-lenght OspA C-terminal domain containing protein fragments in urine. d Nanotrap antigen test results 
on a representative sub-group of the 117 healthy volunteers (Table 1). Lane 1 ladder, lane 2 Bb antigen 1 ng; Lanes 3–12 example of patient urine 
samples demonstrating absence of OspA. e The OspA band is not detectable in the urine of acute stage Lyme patients after successful treatment. 
Lane 1 ladder; lane 2 Bb Lyme antigen Grade 2 in urine 0.1 ng; lane 3 negative control urine with no OspA; lane 4 Initial solution (=urine without 
Nanotrap particle pre-processing) of patient 120 before treatment; lane 5 eluate of patient 120 before treatment; lane 6 Initial solution patient 120 
after treatment; lane 7 Eluate patient 120 after treatment
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32  kDa. The existence of these fragments may indicate 
in vivo degradation of the antigen, since we have estab-
lished that Nanotrap particle capture fully stabilizes the 
captured analyte and prevents enzymatic degradation 
[18, 19, 60].
Correlation of urinary OspA protein with positive Lyme 
borreliosis serology and persistence of symptoms
The clinical diagnosis of acute early stage LB is often 
based on the history of deer tick exposure and clinical 
evaluation of skin lesions for which the appearance is 
quite variable and the differentiation from arthropod bite 
reactions, gyrate erythemas and other erythematous skin 
conditions can be difficult [61]. In 10 % of patients LB is 
not considered and many patients are misdiagnosed (in 
one study 37 % [61]). The literature is mixed in relation 
to the incidence of this hallmark clinical feature of acute 
Lyme disease, ranging from as low as 25 % [4] to as high 
as 80  % [3]. The caveat from this observation is that a 
potentially substantial number of individuals presenting 
with acute Lyme disease will not manifest this derma-
tologic feature. But perhaps more likely with a nonspe-
cific “flu-like” illness. In fact, Feder stated that “patients 
from Lyme disease endemic areas who have fever and 
fatigue, especially within a month following a deer tick 
bite, should be considered for empiric antibiotic therapy 
for early localized Lyme disease”, regardless of whether an 
EM rash is present [62]. We now present technology that 
may provide additional objective information to assist the 
clinical diagnosis and to monitor antigen shedding dur-
ing the course of therapy.
A potential value of the urinary assay reported in this 
study is the evaluation of whether an initial course of 
therapy is sufficient to eradicate the infection. In 1994 
Shadick et al. [40] evaluated 38 adult patients diagnosed 
with Lyme disease, having fulfilled establish serologic 
criteria at the time of the study. Initial antibiotic treat-
ments ranged from 10 to 21 days of a standard regimen. 
Ten of 38 patients with Lyme disease reported relapses 
within 1  year of treatment (fatigue, persistent arthri-
tis or arthralgias, headaches, or difficulty with memory 
and concentration). In 2014, Aucott, et  al. [63] assessed 
the clinical response of 77 individuals presenting with an 
acute EM rash and completing a standard 3 week course 
of doxycycline. After 6  months, 39  % of this group had 
persistent functional impairment and/or persistence 
of new symptoms felt to be related to the acute infec-
tion. In 1999 Oksi et al. reported the clinical relapses of 
disseminated LB confirmed by culture and PCR, with 
various clinical presentations such as arthritis, neuropa-
thy and uveitis [39]. Potential mechanisms contribut-
ing to this persistence of B. burgdorferi in human [39] 
and animal models [64–67] have been identified. These 
include: immune evasion via physical seclusion of Bb 
within immunologically protected tissue sites such as 
the CNS, joints and eyes [67–69], collagen-rich tissue 
[70], cells [71–74], and biofilms [75]; alterations in Osp 
profiles through antigenic variation [76–79], phasic vari-
ation [56], and alteration in Bb morphology (including 
cell-wall deficient forms, spherocytes and ‘cyst’ forms) 
[80–87]; immune modulation via alterations in comple-
ment [88–90], neutrophil and dendritic cell functioning 
Table 2 Urinary OspA results compared to  serology, clinical diagnosis and  treatment status of  N =  168 patients sus-
pected of having early stage LB, and healthy controls
OspA pos urinary OspA test positive, OspA neg urinary OspA test negative, EM Erythema Migrans, ND serology not done




Non Lyme Asymptomatic (EM Neg, serology ND) 117 0 117
Symptomatic, joint pain (EM Neg, serology Neg) 3 0 3
Untreated, clinical diagnosis of LB EM Pos (serology: 12 Pos, 5 Neg, 3 Eq. 4 ND) 24 24 0
Antibiotic treatment for a clinical  
diagnosis of LB
EM rash present at the time of urine collection during  
the treatment course (Serology: 4 Pos, 6 Neg)
10 10 0
Arthritis Pos, EM Neg (serology: 6 Pos) 6 6 0
Converted to EM Neg (Serology: 4 Pos, 4 Neg, 8/8  
urinary OspA Pos prior to therapy)
8 0 8
Table 3 Correlation of urinary OspA to serology CDC crite-
ria for early stage LB
Chi square calculations were obtained including negative asymptomatic healthy 




















OspA Pos 21 17 3 41
OspA Neg 3 124 0 127
Total 24 141 3 168
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[91, 92], and changes in cytokine and chemokine levels 
[93–95] and innate antibiotic tolerance of some B. burg-
dorferi populations [96]. Theoretically, Nanotrap technol-
ogy would have the capacity to determine which, if any 
of these individuals had perpetuation of their symptoms 
due to ongoing infection.
Antibodies specific to B. burgdorferi proteins can take 
three to four weeks to develop [97], and early stage Lyme 
disease, prior to the appearance of a serologic titer, is 
extremely difficult to diagnose due to the low sensitiv-
ity of current diagnostic tests for B. burgdorferi antigen 
[98]. For this reason, treating physicians worry that Lyme 
serology is unreliable for early stage disease because the 
development of antibodies differs widely, especially in 
the early stages of the infection [99, 100]. In prior stud-
ies [61], only 43 % had a positive serology at the time of 
cutaneous EM positive LB diagnosis. Thus, the inflam-
matory reaction manifest in the border of the LB EM 
rash contains proliferating spirochetes and the inflamma-
tory infiltrate is the result of innate immune recognition 
of OspA. By definition it would be expected that OspA 
protein antigen would be shed into the circulation and 
be concentrated in the urine for a significant time period 
prior to the development of a positive serology with 5 
IgG bands as specified under CDC guidelines [99].
Prior to antibiotic treatment, in this study, 24/24 
patients with an EM rash contained OspA protein in 
the urine, verified by peptide competition. Our analy-
sis was blinded to outcome. Based on the sensitivity 
and dose response of the assay, the concentration range 
was between 1.7 and 30 pg/mL. 5 of these 24 early stage 
patients were serology negative and 3 had an equivo-
cal serology at the time of urine collection and clinical 
diagnosis. Following antibiotic therapy of patients with 
a clinical diagnosis of LB, 10/14 patients with a positive 
serology were found to be positive for urinary OspA in 
this study. Following antibiotic therapy for a clinical 
diagnosis of LB, 10 patients in this study were serology 
negative. 4/10 of these post-treatment patients were neg-
ative for urinary OspA. Importantly, for 10 patients who 
exhibited persistence of the EM rash during the course of 
antibiotic therapy, 10/10 were positive for urinary OspA. 
In contrast 4/10 of these same patients who had the EM 
rash during antibiotic therapy ultimately became serol-
ogy positive. Urinary OspA measurement of 8 patients 
for whom the therapeutic response was judged com-
plete (absence of EM rash and absence of symptoms) 
following antibiotic therapy revealed that all 8 patients 
switched from being urinary OspA positive to urinary 
OspA negative (Table 2). 4 of these 8 patients were sub-
sequently found to be serology positive for Bb infection. 
These data are in keeping with the correlation of urinary 
shed of OspA and the presence of concurrent objective 
symptoms (EM rash). When CDC criteria serology, and 
in accord with the Infectious Diseases Society of Amer-
ica (IDSA), was compared to urinary OspA regardless 
of pre or post treatment status of early stage LB, 87.5 % 
of serology positive were also urinary OspA positive 
and 88  % of serology negative were also urinary OspA 
negative (Chi squared p value =  4.072e−15; significance 
level =  5  %, power =  99.99  %, Table  3). The remaining 
12  % of patients who were urinary OspA positive who 
were serology negative demonstrated positive symptoms 
qualifying for clinical diagnosis of LB and may not have 
yet mounted an antibody response.
In this study, 100 % of pre and post treatment samples 
that had active symptoms were found to be positive for 
detectable urinary OspA (40/40, Table 2). Urinary OspA 
outcome (positive) was significantly associated with pres-
ence of clinical symptoms (EM rash, Chi squared p value 
<2.2e−16; significance level = 5 %, power = 100 %).
Of these 40 patients, 22 were serology positive by CDC 
standards for early stage disease [33]. This is in keeping 
with prior studies showing positive serology in approxi-
mately 50  % of early stage cutaneous LB patients [61]. 
Early prompt treatment of LB is known to blunt the 
serology response because the infection and immune 
response is being interrupted at an early stage [101, 102].
Urinary OspA in patients suspected of having “chronic” LB
Lyme disease is too often diagnosed after the infection 
is well established and the patient has raised an antibody 
titer against the bacteria B. burgdorferi [98]. Persistent 
LB, treatment resistant, recurrent, or a new LB is also 
extremely difficult to diagnose when the serologic titer 
is equivocal or if the patient has persistent symptoms 
(e.g. neurologic, arthritic, or dermatologic) in the face of 
therapy. Unfortunately patients with clinical history of 
LB (serology positive or serology inconclusive) can pre-
sent with articular and neuromuscolar symptoms. Lack 
of response to treatment can theoretically be due to per-
sistence of infection via one or more mechanims already 
discussed, such as sequestration in tissue or biofilm. 
Given the polymicrobial nature of tick borne illnesses, 
infection with one or more different pathogens is a con-
sideration [103–113]. On the other hand, persistence of 
symptoms has been postulated to be the result of a new 
LB infection [103], or perhaps to improper diagnosis of 
LB and unrelated co-existing musculoskeletal morbidity 
or to persistence of infection in a sequestered tissue such 
as joint cartilage [9], or biofilm [75, 114, 115].
In this study, we evaluated the level of urinary OspA 
protein in 100 previously or currently treated patients 
with joint, neurologic, and other objective symptoms 
(Additional file  1: Table  S6). This group of patients 
were being evaluated for the potential of recurrent or 
Page 18 of 22Magni et al. J Transl Med  (2015) 13:346 
persistent infection with Borrelia. Our analysis was 
blinded to outcome. 41 of 100 (41 %) patients were posi-
tive for urinary OspA protein. This percentage of posi-
tive urinary OspA, assuming that it reflects a specific 
infection by Bb that is shedding OspA C-terminal frag-
ments, is in keeping with prior studies. Patients evalu-
ated in endemic LB regions who presented with arthritis 
and neurologic symptoms were estimated to have active 
and prior LB (7–31  % active disease and 5–20  % previ-
ous Lyme disease in endemic areas [43–48]). IDSA and 
ILADS differ in their recommendations for the clini-
cal assessment and treatment of persistent LB. A highly 
specific antigen test for Borrelia proteins might provide 
new class of evidence to refine the guidelines for diagno-
sis and treatment of LB. It is widely acknowledged that 
patients suspected of having chronic Lyme borreliosis 
based neurologic or joint symptomatology may not truly 
have Lyme borreliosis, or may have other tick borne dis-
eases. Therefore in patients who are suspected of having 
chronic Lyme disease, as evaluated in the present study, 
there has not been a means to assess the true positive 
patients. Most, if not all, of these patients have a nega-
tive Lyme serology by the 2 tier criteria. Thus our find-
ings of 41  % positive patients in this population cannot 
be defined as a level of sensitivity and specificity, since 
none, or all, of these patients could actually have had an 
active Borrelia infection. Importantly, our data provides 
the first antigenic evidence that at least 41  % of these 
patients may have an active Bb infection. Therefore these 
data contribute significant new information to the debate 
about chronic Lyme disease.
Conclusions
These data support the hypothesis that urinary OspA 
protein fragments containing the C-terminal domain 
occur prior to the development of a full IgG serology 
response, and urinary OspA strongly correlates with 
a clinical diagnosis and active clinical symptoms (e.g. 
EM rash positive) of early stage LB. Thus, this technol-
ogy has the potential to provide clarity in the setting of 
individuals at risk of tick exposure and acutely present-
ing with either an atypical EM rash or without a rash at 
all, but consistent with the nonspecific findings of acute 
Lyme. Moreover, persistence of objective clinical mani-
festations in these patients was accompanied by contin-
ued shedding of urinary OspA even during the course 
of treatment. In contrast, after successful resolution of 
symptoms in promptly treated early stage LB, urinary 
OspA protein became undetectable (Table 2).
Antigenuria in the setting of chronic persistent 
symptoms may be due to new, acute infectious expo-
sures. Alternatively, antigenuria detected in individu-
als with consistent, persistent symptoms would warrant 
consideration of an ongoing active infection, supportive 
of the concept of LB in the chronic active state.
PCR analysis of urinary Borrelia, or urinary Borrelia 
culture was not done, because of the very low sensitiv-
ity of these tests in human urine [28]. Consequently, a 
weakness of this study is that a true positive diagnosis 
of LB could only be based on the CDC clinical criteria 
(e.g. EM rash and other objective symptoms), and the 
development of a later positive serology in patients who 
underwent therapy at the time of the clinical diagnosis 
of LB. Despite this weakness, the strong correlation of 
urinary OspA with treatment response may offer a new 
class of information to assist the treating physician to 
determine whether a first round of therapy is successful 
in primary cutaneous early stage LB. In a population of 
patients being under surveillance for persistent or recur-
rent LB, the percentage of positive urinary OspA patients 
is in keeping with previous studies on patients estimated 
to actually have LB in endemic areas. It is impossible to 
know if urinary OspA, assuming that is indicative of Bb 
infection, is caused by a recurrent or new infection. Uri-
nary OspA measurements may provide additional infor-
mation to assist the clinical workup of patients under 
investigation of disseminated later stages of LB. We are 
attempting to validate the correlation of urinary OspA 
antigen with therapeutic response in an ongoing clinical 
study which extends the current findings.
Additional file
Additional file 1.Figure S1. 81 % of the total protein present in Bb 
Lyme antigen Grade 2 (American Research Products) is constituted by 
OspA. A dilution of a recombinant purified OspA protein (Genecopoeia) 
was analyzed by SDS PAGE and silver stained (100 to 1,000 ng, Lanes 
3–7). The band intensities were quantified using ImageJ software and a 
calibration curve was built (insert graph). A linear regression curve was 
fitted (y = 5.39x+12281, R2 = 0.9873). 500 ng of Bb Lyme antigen Grade 2 
were loaded on the gel (Lane 2) and compared to the recombinant OspA 
calibration curve (Lanes 3–7). From this procedure it derived that 81% of 
Bb Lyme antigen Grade 2 total protein content is OspA. In gel protein 
digestion and mass spectrometry (MS) analysis verified the predominant 
presence of tryptic peptides belonging to OspA in the bands at ~30 kDa 
and ~60 kDa present both in the Bb Lyme antigen Grade 2 and in the 
recombinant OspA. In particular, tryptic peptides containing the epitope 
for mAb clone 0551 OspA236-239 were present in both bands (MS-MS 
spectra are reported in the insert). Figure S2. Narrow OspA236-239 
region binds to mAb clone 0551 with high specificity. Dot blot analysis 
revealed that only 2 out of 7 synthetic peptides with sequence reported 
in Table S1 show reactivity with the anti OspA monoclonal antibody 
clone 0551 used in this study. Figure S3.  Light scattering analysis was 
used to determine the hydrodynamic diameter of the Nanotrap particles. 
As reported in Table S2, the hydrodynamic diameter of the Nanotrap 
particles was 1054.7 +/- 31.11 nm. Figure S4.  A V/v ratio (V = Nanotrap 
suspension volume, v = sample volume) of 1/10 was optimized in order 
to maximize Lyme antigen capturing. a 2 ng of Lyme antigen was spiked 
in 500 µL urine aliquots. Urine samples were incubated with increasing 
amount of Nanotrap particle suspension (10–160 µL of Nanotrap at 5 mg/
mL concentration). Lane 1 ladder; lane 2 Positive control (OspA 1ng); lane 
3 10 µL of Nanotrap particles; lane 4 20  µL Nanotrap particles; lane 5 
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40 µL Nanotrap particles; lane 6 80 µL Nanotrap particles; lane 7 160 µL 
Nanotrap particles; b Band intensity was measured with ImageJ, plateau 
is reached with >40 µL of Nanotrap particles. Figure S5. Interfering sub-
stances: the presence of a high amount of protein and blood in the urine 
does not interfere with Lyme antigen capture and detection. a 320 pg of 
Lyme antigen was spiked in samples of 40 mL of human urine. We tested 
the interference of albumin present in excess up to 10^8 fold. Increas-
ing amounts of bovine serum albumin ranging from 0.31 mg/mL to 20 
mg/mL were added to 40 mL of OspA containing human urine; urine 
samples were processed with Nanotrap particles. Ability of the Nanotrap 
particles to sequester OspA is not affected by increasing concentration of 
competing proteins in urine. Lane 1 ladder; lane 2 volunteer human urine 
in absence of OspA antigen (negative control); lane 3 OspA + BSA 20 mg/
mL; lane 4 OspA + BSA 10 mg/mL; lane 5 OspA + BSA 5 mg/mL; lane 6 
OspA + BSA 2.5 mg/mL; lane 7 OspA + BSA 1.25 mg/mL; lane 8 OspA + 
BSA 0.625 mg/mL; lane 9 OspA + BSA 0.31 mg/mL; lane 10 OspA + BSA 
0.15 mg/mL. b Lyme antigen 320 pg was spiked in urine samples (40 mL). 
Increasing amounts of whole blood from 0.015 µL to 1 µL was added to 
the urine samples; urine samples were processed with Nanotrap particles 
and analyzed using western blot. Lane 1 ladder; lane 2 volunteer human 
urine in absence of OspA antigen (negative control); lane 3 OspA + 1 µL 
whole blood; lane 4 OspA + 0.5 µL whole blood; lane 5 OspA + 0.25 µL 
whole blood; lane 6 OspA + 0.125 µL whole blood; lane 7 OspA + 0.062 
µL whole blood; lane 8 OspA + 0.031 µL whole blood; lane 9 OspA + 
0.015 µL whole blood; lane 10 OspA + 0.007 µL whole blood. Figure S6. 
a Nanotrap particle preprocessing step is necessary to detect an OspA 
specific band in the urine of patient PD113, clinically positive for Lyme 
disease. Initial solution (IS) before Nanotrap particle processing. Eluate 
(E) after Nanotrap particle processing. b Positive and negative controls 
run with all Lyme patient samples. Lane 2 contains borrelia protein 
lysate (2 ng) in human urine. Lane 5 is a positive control 4 ng spiked in 
40 mL of urine sample. Lane 6 and 7 are negative controls of 40 mL of 
volunteer urine processed through the Nanotrap particles. C=borrelia 
lysate control, IS=initial solution, S=supernatant, E=eluate. Table S1. 
Sequences of peptides tested for antibody binding. Table S2. The mAb 
epitope used herein (red rectangle) is conserved in common pathogenic 
species of Borrelia. BAA22342.1 in Borrelia garinii Taxonomy ID 29519, 
ADD14639.1 in Borrelia burgdorferi taxonomy ID 139, WP_012665647.1 
in Borrelia valaisiana taxonomy ID 62088, WP_012665647.1 in Borrelia sp. 
SV1 taxonomy ID 498741, YP_003110622.1 in Borrelia burgdorferi 297 
taxonomy ID 521009, NP_045688.1 in Borrelia burgdorferi B31 taxonomy 
ID 224326, WP_014023199.1 in Borrelia bissettii taxonomy ID 64897, 
ADG02035.1 in Borrelia afzelii taxonomy ID 29518, AAN65460.1 in Borrelia 
spielmanii taxonomy ID 88916. BLAST analysis was performed on the 
sequence KTSTLTISVNSKTTQLVFTKQDTITVQKYDSAGT (combination of 
peptide 5 and 6) with the following organisms: Treponema pertenue 
(taxonomy ID 168), Leptospiraceae (taxonomy ID 170), Treponema 
(taxonomy ID 157), Spirochaetes (taxonomy ID 203691) excluding Borrelia 
(taxonomy ID 138), Homo sapiens (taxonomy ID 9606), Epstein-Barr virus 
EBV (taxid:10376), Human cytomegalovirus (taxid:10359), herpes simplex 
virus 1 HSV-1 (taxid:10298), hepatitis C virus HCV (taxid:11103), Babesia 
txid5864, Anaplasma txid768, Ehrlichieae txid942, Bartonella  txid773, 
Rickettsias txid766.  No significant similarity found.  No homology was 
identified. Table S3. Light scattering analysis of Nanotrap particles. Table 
S4. Quantification of the amount of Remazol brilliant blue (RBB) dye 
covalently bound to the Nanotrap particles and percentage of reacted 
acrylic acid (AAc) moles. This information was obtained and recorded for 
every batch of produced Nanotrap particles (example batch # RM37B4 is 
reported here). Table S5. Clinical and diagnostic information of patients 
suspected of having early stage Lyme disease N=51 (N= 117 healthy 
volunteers were recruited under informed consent and included in the 
study). Treatment: Dx = doxycycline, Pd = prednisone, RC = rocepherin, 
sv = synovectomy, st = steroids, Am = amoxil, Zm = Zithromax. Urine 
collection timing and presence of symptoms: B = before treatment, PT 
= during or after treatment, symptoms present at the time urine was 
collected. Table S6. Post treatment patients being evaluated for recurrent 
or persistent disseminated Lyme disease derived from a Lyme endemic 
geographic region.
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